

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** Confirmed

**Date and Time:** Thursday 9 July 2015

**Venue:** Prospero House  
241 Borough High Street  
London  
SE1 1GA

<b>Present:</b>	1. Chair, Dr Amanda Adler	Present for all notes
	2. Vice Chair, Professor Ruairidh Milne	Present for all notes
	3. Dr Jeff Aronson	Present for all notes
	4. Professor John Cairns	Present for all notes
	5. Professor Imran Chaudhry	Present for all notes
	6. Dr Neil Iosson	Present for all notes
	7. Mrs Anne Joshua	Present for all notes
	8. Dr Sanjay Kinra	Present for all notes
	9. Dr Miriam McCarthy	Present for all notes
	10. Mr Chris O'Regan	Present for all notes
	11. Professor Stephen Palmer	Present for all notes
	12. Dr Sanjeev Patel	Present for all notes
	13. Dr John Pounsford	Present for all notes
	14. Dr Danielle Preedy	Present for all notes
	15. Mr Alun Roebuck	Present for all notes
	16. Dr Nicky Welton	Present for all notes

### In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Elisabeth George	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Stuart Wood	Administrator, National Institute for Health and Care Excellence	Present for all notes
Dr Mary Hughes	Technical Analyst,	Present for all notes

National Institute for  
Health and Care  
Excellence

Eleanor Donegan	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
Ewen Cummins	Health Economist, Evidence Review Group – Aberdeen	Present for notes 1 to 16
Dr Craig Ramsay	HCA Programme Director and Senior Statistician, Evidence Review Group – Aberdeen	Present for notes 1 to 16

**Non-public observers:**

Rebecca Dittrich	NICE International	Present for all notes
Jeremy Rodrigues	NICE Fellow	Present for al notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy
2. The Chair informed the Committee of the non-public observers at this meeting: Rebecca Dittrich and Jeremy Rodrigues
3. Apologies were received from Dr Ray Armstrong, Mr Mark Chapman, Professor Daniel Hochhauser, Professor Ken Stein and Dr Marta Soares.

**Any other Business**

4. None

**Notes from the last meeting**

5. The minutes from the 14 May and 11 June committee meeting were approved.

**Appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy**

**Part 1 – Open session**

6. The Chair welcomed the invited evidence review group: Ewen Cummins and Dr Craig Ramsay to the meeting and they introduced themselves to the Committee.

7. The Chair welcomed company representatives from Astellas to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
  - 8.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Professor Imran Chaudhry, Dr Neil Iosson, Mrs Anne Joshua, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Christopher O'Regan, Professor Stephen Palmer, Dr Sanjeev Patel, Dr John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck and Dr Nicky Welton all declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
9. The Chair asked all NICE Staff to declare any relevant interests.
  - 9.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
10. The Chair asked the ERG to declare their relevant interests.
  - 10.1. All declared that they knew of no personal specific pecuniary interest, personal non-specific pecuniary interest, non-personal specific pecuniary interest, non-personal non-specific pecuniary interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy.
11. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
12. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy on the basis of the evidence before them. The discussions included:
  - 12.1. The comments from consultation relating to the use of abiraterone in current clinical practice and whether abiraterone was a relevant comparator
  - 12.2. The additional information provided by the company relating to how it adjusted the overall survival estimates from PREVAIL for treatments not used in the NHS and the rationale for its approach to extrapolating data in the model

- 12.3. Whether the PPRS rebate was relevant to the cost effectiveness estimates and to its decision making
  - 12.4. The modelling assumptions stated to be the most plausible in the appraisal consultation document, and whether any of the comments received from consultation had changed its views on these
  - 12.5. The incremental cost effectiveness analysis enzalutamide
- 13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  - 14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
  - 15. The Chair then thanked the experts, company representatives and academic group for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

- 16. Discussion continued on confidential information. This information was supplied by the company.
- 17. The Committee continued to discuss the clinical and cost effectiveness of enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with cytotoxic chemotherapy
- 18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

- 19. Wednesday 12 August, 10.00am to 5.00pm at Prospero House, 241 Borough High Street, London, SE1 1GA.